Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00812396 | Biomarkers of Muscle Anabolism (MK-0000-082) | PHASE1 | COMPLETED | 30 | — | — | Nov 1, 2007 | Feb 1, 2008 | Jan 30, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Low dose testosterone |
| 2 | ACTIVE_COMPARATOR | High dose testosterone |
| 3 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Comparator: low dose testosterone | DRUG | Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone. |
| Comparator: high dose testosterone | DRUG | Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone. |
| Comparator: placebo | DRUG | Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution. |
Inclusion Criteria: * subject is a healthy male between 18 and 40 years old * subject's weight is stable over the past 3 months * subject agrees to refrain from consuming alcohol during study * subject agrees to consume no caffeine while in the CRU * subject agrees to follow meat-free diet * subjec...